Shanghai, China and New York, NY (Press Release) – Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a bio­pharma­ceu­tical firm engaged in the devel­op­ment of immuno­therapies for cancer and stem cell ther­a­pies for degenerative diseases, today announces the initiation of patient recruitment to sup­port the study of anti-BCMA CAR-T ther­apy targeting re­lapsed and refractory multiple myeloma in China.

"China has seen a sub­stan­tial in­­crease in the in­ci­dence of multiple myeloma. As a drug devel­op­ment com­pany, BCMA is the first of multiple assets that CBMG is ad­vanc­ing amongst our on­col­ogy pipe­line beyond our col­lab­o­ration with a …

Summit, NJ and Cambridge, MA (Press Release) – Celgene Corpo­ra­tion (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) to­day an­nounced the com­ple­tion of en­roll­ment for the KarMMa pivotal study of bb2121, the com­pa­nies’ lead inves­ti­ga­tional anti-BCMA CAR T cell ther­apy can­di­date for patients with re­lapsed and re­frac­tory mul­ti­ple myeloma. bb2121 is being devel­oped as part of a Co-Development, Co-Promote and Profit Share Agreement be­tween Celgene and bluebird bio.

“We con­tinue to be ex­cited about bb2121 as a poten­tial first-in-class BCMA-targeted ther­apy for patients with mul­ti­ple myeloma,” said Alise Reicin, M.D., Pres­i­dent, Global …

• SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma
• Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors

Bothell, WA (Press Release) – Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clin­i­cal trial eval­u­ating the safety and tolerability of SEA-BCMA for patients with re­lapsed or refractory multiple myeloma (MM). SEA-BCMA is an inves­ti­ga­tional anti­body empowered using Seattle Genetics’ pro­pri­e­tary Sugar Engineered Antibody (SEA) tech­nology designed to en­hance anti­body dependent cellular cyto­tox­icity. …

San Diego, CA (Press Release) – Poseida Therapeutics Inc., a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on leveraging pro­pri­e­tary next-generation, non-viral gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics, today announced the U.S. Food and Drug Admin­istra­tion (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) desig­na­tion to P-BCMA-101, Poseida’s lead CAR-T thera­peutic can­di­date cur­rently in a Phase 1 clin­i­cal trial for the treat­ment of patients with re­lapsed / refractory multiple myeloma. RMAT desig­na­tion in­cludes all of the benefits of the Fast Track and Break­through Therapy desig­na­tion pro­grams, in­­clud­ing early inter­actions with the FDA.

“P-BCMA-101 is the …

• Efficacy and safety con­tinue to be a major ad­van­tage, with a very high response rate, no dose limiting toxicities and only a single in­ci­dence of sus­pected cytokine release syn­drome
• P-BCMA-101 clin­i­cal data as well as pre­clin­i­cal data from MUC1C and PSMA solid tumor pro­grams and BCMA allo­geneic pro­gram presented at the CAR-TCR Summit

San Diego, CA (Press Release) – Poseida Therapeutics Inc. (“Poseida”), a clin­i­cal-stage bio­tech­nology com­pany translating best-in-class gene engi­neer­ing tech­nolo­gies into lifesaving cell ther­a­pies, announced data results from the first eleven patients treated in its ongoing Phase 1 study of its P-BCMA-101 stem cell memory chi­meric an­ti­gen re­cep­tor T-cell (CAR-T) prod­uct in re­lapsed / refractory multiple myeloma. All eleven patients remain on study with seven of ten patients evaluable by Inter­na­tional Myeloma Work­ing Group (IMWG) criteria achieving at least a partial response. The remaining patient also dem­onstrated …

Updated re­­sults of a Phase 1 trial testing bb2121 in re­lapsed mul­ti­ple myeloma patients were pre­sented last Friday at the American Society of Clinical Oncology (ASCO) annual meeting. bb2121 is a poten­tial new myeloma treat­ment in the chi­meric an­ti­gen re­cep­tor (CAR) T-cell class of ther­a­pies.

The re­­sults pre­sented at this year's ASCO meeting con­firm pre­vi­ous findings in­di­cating bb2121 has sub­stan­tial anti-myeloma ac­­tiv­ity.

At some of the higher doses of bb2121 tested during the trial, for example, nearly every patient treated with the drug responded to it; the over­all re­sponse rate was almost …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began last Friday and will run through tomorrow.

Multiple myeloma-related pre­sen­ta­tions have been taking place every day of the meeting. The main myeloma-related oral pre­sen­ta­tion session of the meeting, how­ever, took place on Friday. Research summarized during oral pre­sen­ta­tion sessions usually is par­tic­u­larly im­por­tant, either because the subject itself is im­por­tant, or because the results are based on sub­stan­tial amounts of evi­dence (for example, a sizable clin­i­cal trial).

Given the poten­tial importance of the re­search results pre­sented last Friday, The Beacon asked …